AAO-HNS GUIDELINES Bundle (free trial)

Immunotherapy for Inhalant Allergy

American Academy of Otolaryngology-Head and Neck Surgery Foundation GUIDELINES Apps brought to you free pf charge, courtesy of Guideline Central. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1516464

Contents of this Issue


Page 1 of 15

2 Introduction ➤ Allergic rhinitis (AR) and allergic asthma (AA) are caused by an immunoglobulin E (IgE) mediated inflammatory response to proteins (or glycoproteins) carried by inhaled organic particles such as pollen, animal dander, mold spores, and/or mite/insect debris. ➤ Inhalant allergies can be treated by immunotherapy, pharmaceuticals, or by reducing environmental exposure to the allergen. ➤ Inhalant allergen immunotherapy (AIT) is administered to millions of patients for AR and AA and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT). ➤ Variability in the initiation and delivery of safe and effective immunotherapy provides opportunities for evidence-based recommendations to improve patient care.

Articles in this issue

Archives of this issue

view archives of AAO-HNS GUIDELINES Bundle (free trial) - Immunotherapy for Inhalant Allergy